BACKGROUND: Delayed initiation of antiretroviral therapy (ART) in eligible patients is a concern in resource-limited countries. METHODS: We analyzed data on HIV-positive patients ≥15 years enrolled at 41 ICAP-supported health care facilities in Rwanda, 2005-2010, to determine time to ART initiation among patients eligible at enrollment compared with those ineligible or of indeterminate eligibility who become eligible during follow-up. ART eligibility was based on CD4 cell count (CD4) and WHO staging; patients lacking CD4 and WHO stage were considered indeterminate. Cumulative incidence of reaching ART eligibility and to ART initiation after eligibility was generated using competing risk estimators. RESULTS: A total of 31,033 ART-naive adults were enrolled; 64.2% were female. At enrollment, 10,158 (32.7%) patients were ART eligible, 13,372 (43.1%) were ineligible for ART, and 7503 (24.2%) patients were indeterminate. Among patients retained in care pre-ART eligibility, 17.9% [95% confidence interval (CI): 17.2 to 18.6] of ineligible and 22.8% (95% CI: 21.7 to 23.8) of indeterminate patients at enrollment reached ART eligibility within 12 months. Cumulative incidence of ART initiation within 3 months for patients eligible at enrollment was 77.2% (95% CI: 76.4 to 78.0) compared with 67.9% (95% CI: 66.4 to 69.3) for ineligible and 63.8% (95% CI: 61.9 to 65.8) for patients with indeterminate eligibility at enrollment (P < 0.05). Over the study period, there was more rapid ART initiation for patients who became ART eligible. CONCLUSIONS: We found higher rates of ART initiation within 3 months among patients who were ART eligible at enrollment compared with those who reached eligibility during follow-up. From 2006 to 2011, earlier initiation of ART after eligibility was observed likely reflecting improved program quality.
BACKGROUND: Delayed initiation of antiretroviral therapy (ART) in eligible patients is a concern in resource-limited countries. METHODS: We analyzed data on HIV-positive patients ≥15 years enrolled at 41 ICAP-supported health care facilities in Rwanda, 2005-2010, to determine time to ART initiation among patients eligible at enrollment compared with those ineligible or of indeterminate eligibility who become eligible during follow-up. ART eligibility was based on CD4 cell count (CD4) and WHO staging; patients lacking CD4 and WHO stage were considered indeterminate. Cumulative incidence of reaching ART eligibility and to ART initiation after eligibility was generated using competing risk estimators. RESULTS: A total of 31,033 ART-naive adults were enrolled; 64.2% were female. At enrollment, 10,158 (32.7%) patients were ART eligible, 13,372 (43.1%) were ineligible for ART, and 7503 (24.2%) patients were indeterminate. Among patients retained in care pre-ART eligibility, 17.9% [95% confidence interval (CI): 17.2 to 18.6] of ineligible and 22.8% (95% CI: 21.7 to 23.8) of indeterminate patients at enrollment reached ART eligibility within 12 months. Cumulative incidence of ART initiation within 3 months for patients eligible at enrollment was 77.2% (95% CI: 76.4 to 78.0) compared with 67.9% (95% CI: 66.4 to 69.3) for ineligible and 63.8% (95% CI: 61.9 to 65.8) for patients with indeterminate eligibility at enrollment (P < 0.05). Over the study period, there was more rapid ART initiation for patients who became ART eligible. CONCLUSIONS: We found higher rates of ART initiation within 3 months among patients who were ART eligible at enrollment compared with those who reached eligibility during follow-up. From 2006 to 2011, earlier initiation of ART after eligibility was observed likely reflecting improved program quality.
Authors: Elvin H Geng; David V Glidden; David R Bangsberg; Mwebesa Bosco Bwana; Nicholas Musinguzi; Denis Nash; John Z Metcalfe; Constantin T Yiannoutsos; Jeffrey N Martin; Maya L Petersen Journal: Am J Epidemiol Date: 2012-02-03 Impact factor: 4.897
Authors: Michael L Rich; Ann C Miller; Peter Niyigena; Molly F Franke; Jean Bosco Niyonzima; Adrienne Socci; Peter C Drobac; Massudi Hakizamungu; Alishya Mayfield; Robert Ruhayisha; Henry Epino; Sara Stulac; Corrado Cancedda; Adolph Karamaga; Saleh Niyonzima; Chase Yarbrough; Julia Fleming; Cheryl Amoroso; Joia Mukherjee; Megan Murray; Paul Farmer; Agnes Binagwaho Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: R A Murphy; H Sunpath; B Taha; S Kappagoda; K T M Maphasa; D R Kuritzkes; L Smeaton Journal: Int J Tuberc Lung Dis Date: 2010-07 Impact factor: 2.373
Authors: Nuala McGrath; Judith R Glynn; Jacqueline Saul; Katharina Kranzer; Andreas Jahn; Frank Mwaungulu; Msenga H C Ngwira; Hazzie Mvula; Fipson Munthali; Venance Mwinuka; Lorren Mwaungulu; Paul E M Fine; Amelia C Crampin Journal: BMC Public Health Date: 2010-10-12 Impact factor: 3.295
Authors: Jennifer Namusobya; Fred C Semitala; Gideon Amanyire; Jane Kabami; Gabriel Chamie; John Bogere; Vivek Jain; Tamara D Clark; Edwin Charlebois; Diane V Havlir; Moses Kamya; Elvin H Geng Journal: Clin Infect Dis Date: 2013-07-29 Impact factor: 9.079
Authors: Muktar H Aliyu; Meridith Blevins; Deidra D Parrish; Karen M Megazzini; Usman I Gebi; Mukhtar Y Muhammad; Mukhtar L Ahmed; Adiba Hassan; Bryan E Shepherd; Sten H Vermund; C William Wester Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Katharina Kranzer; Darshini Govindasamy; Nathan Ford; Victoria Johnston; Stephen D Lawn Journal: J Int AIDS Soc Date: 2012-11-19 Impact factor: 5.396
Authors: Jeremy Philip Brown; Bagrey Ngwira; Terence Tafatatha; Amelia Catharine Crampin; Neil French; Olivier Koole Journal: AIDS Res Ther Date: 2016-07-08 Impact factor: 2.250